Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy
暂无分享,去创建一个
F. Zaccardi | G. Ghirlanda | G. Scavone | D. Pitocco | S. Caputo | L. Mancini | M. Galli | E. di Stasio | F. Martini | G. Zelano | T. Musella | G. Gioffrè
[1] E. Weledji,et al. The Diabetic Foot , 2015 .
[2] Allen H. Hamdan,et al. Management of diabetic foot problems. , 2010, Journal of vascular surgery.
[3] K. Weiss,et al. Charcot arthropathy risk elevation in the obese diabetic population. , 2008, The American journal of medicine.
[4] P. Tonin,et al. Diabetes and osteoporosis , 2008, Aging clinical and experimental research.
[5] E. Rahme,et al. Osteoporosis among patients with type 1 and type 2 diabetes. , 2008, Diabetes & metabolism.
[6] Kari Stefansson,et al. Multiple genetic loci for bone mineral density and fractures. , 2008, The New England journal of medicine.
[7] M. Edmonds,et al. Increased osteoclastic activity in acute Charcot’s osteoarthopathy: the role of receptor activator of nuclear factor-kappaB ligand , 2008, Diabetologia.
[8] S. Ku,et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-&kgr;B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women , 2007, Menopause.
[9] Laura Herrero,et al. Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.
[10] A. Goldfine,et al. Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.
[11] Kejun Liu,et al. PowerMarker: an integrated analysis environment for genetic marker analysis , 2005, Bioinform..
[12] P. Collin‐Osdoby. Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin , 2004, Circulation research.
[13] Y. Ramot,et al. The diabetic Charcot foot. , 2004, The Israel Medical Association journal : IMAJ.
[14] G. Rümenapf,et al. Diabetische neuropathische Osteoarthropathie (Charcot-Fuß) , 2003 .
[15] Kevin J. Tracey,et al. The inflammatory reflex , 2002, Nature.
[16] C. Marcocci,et al. Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. , 2002, Diabetes research and clinical practice.
[17] P. Hudler,et al. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[18] R. Jenkins,et al. Charcot neuroarthropathy in diabetes mellitus , 2002, Diabetologia.
[19] S. Khosla,et al. Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.
[20] M. Edmonds. Progress in care of the diabetic foot , 1999, The Lancet.
[21] D. Armstrong,et al. Is Charcot arthropathy a late sequela of osteoporosis in patients with diabetes mellitus? , 1998, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.
[22] A. Veves,et al. The Prediction of Diabetic Neuropathic Foot Ulceration Using Vibration Perception Thresholds: A prospective study , 1994, Diabetes Care.
[23] J. Adams,et al. Radiographic Abnormalities in the Feet of Patients With Diabetic Neuropathy , 1994, Diabetes Care.
[24] P. Sönksen,et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population , 1993, Diabetologia.
[25] A. Vinik,et al. Diagnosis and management of diabetic autonomic neuropathy , 2003, Comprehensive therapy.
[26] S. Sinha,et al. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). , 1972, Medicine.